Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

Match each palliative care clinical scenario with the most appropriate pharmacological intervention.

  • An 81-year-old with end-stage renal disease and diffuse bone metastases is tolerating 60 mg of oral morphine equivalents daily but requires transition to a continuous, long-acting analgesic for severe pain.Initiate a transdermal fentanyl patch
  • A 67-year-old with metastatic prostate cancer whose opioid dosage was rapidly escalated over three days now presents with new-onset delirium, diffuse hyperalgesia, and spontaneous myoclonic jerks.Perform an opioid rotation to a structurally dissimilar agent at a reduced equianalgesic dose
  • A 78-year-old actively dying patient appears comfortable but exhibits loud, pooling oropharyngeal secretions during inspiration and expiration that are highly distressing to the family at the bedside.Administer subcutaneous glycopyrrolate
  • A 62-year-old opioid-naïve patient with end-stage interstitial lung disease experiences severe air hunger and tachypnea at rest despite maximal supplemental oxygen therapy.Initiate low-dose targeted oral morphine

Cevap

The correct pairings match the end-stage renal disease patient with a transdermal fentanyl patch, the patient exhibiting neurotoxicity with an opioid rotation, the actively dying patient having terminal secretions with glycopyrrolate, and the opioid-naïve dyspneic patient with low-dose oral morphine.
Each pairing directly addresses specific physiological limitations and symptom profiles commonly encountered in palliative care. Fentanyl avoids the accumulation of toxic metabolites in renal failure and is safe due to the patient's existing opioid tolerance. Opioid rotation clears the neurotoxic metabolites causing myoclonus and hyperalgesia. Glycopyrrolate dries terminal secretions without causing central nervous system agitation. Low-dose oral morphine safely targets the central perception of dyspnea in pulmonary failure.

Adım Adım Çözüm

1
Evaluate the patient with end-stage renal disease for appropriate continuous analgesia.
The patient is matched with initiating a transdermal fentanyl patch.
Morphine metabolites accumulate in renal failure, causing toxicity. Fentanyl is safe in renal impairment and is indicated here because the patient is already opioid-tolerant.
2
Identify the cause of the cancer patient's hyperalgesia and myoclonus.
The patient is matched with performing an opioid rotation.
The clinical picture is opioid-induced neurotoxicity. Management requires rotating to a structurally distinct opioid to allow clearance of the accumulated neurotoxic metabolites.
3
Determine the pharmacological treatment for the dying patient's noisy breathing.
The patient is matched with administering subcutaneous glycopyrrolate.
Glycopyrrolate dries terminal secretions effectively and, unlike other anticholinergics, does not cross the blood-brain barrier to cause confusion or agitation.
4
Select the best intervention for the opioid-naïve patient's refractory air hunger.
The patient is matched with initiating low-dose targeted oral morphine.
Systemic opioids are the gold standard for alleviating severe terminal dyspnea. An immediate-release oral formulation is appropriate and safe for an opioid-naïve patient when titrated carefully.

Anahtar Kavram

Pharmacological symptom management in palliative care requires individualizing therapy based on organ function (e.g., using fentanyl over morphine in renal failure), symptom etiology (e.g., low-dose opioids for dyspnea, anticholinergics for terminal secretions), and opioid tolerance.
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru